Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Hua

Showing results (41-50 of 283) with videos related to

Pageof 29
Sort By:
Zhonghua Yi Xue Za Zhi|March 3, 2023
[Opportunities and prospects for sports medicine in China]S Y Chen, Y H Hua, T W Chen
Case Reports in Medicine|June 13, 2012
Concurrent stenoocclusive disease of intracranial and extracranial arteries in a patient with polycythemia veraLe H Hua, Robert L Dodd, Neil E Schwartz
Annals of Internal Medicine|September 15, 1993
A reassessment of the importance of "low-count" bacteriuria in young women with acute urinary symptomsC M Kunin, L V White, T H Hua
Zhonghua Kou Qiang Yi Xue Za Zhi = Zhonghua Kouqiang Yixue Zazhi = Chinese Journal of Stomatology|October 11, 2016
[Accuracy of three methods for the rapid diagnosis of oral candidiasis]X Lyu, C Zhao, Z M Yan, et al.
European Review for Medical and Pharmacological Sciences|August 1, 2019
MiRNA-191 functions as an oncogene in primary glioblastoma by directly targeting NDST1J Xue, M Yang, L-H Hua, et al.
Multiple Sclerosis and Related Disorders|April 17, 2019
Corrigendum to "Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60" [Multiple Sclerosis and Related Disorders 30 (2019) 252-256]Le H Hua, Haleigh Harris, Devon Conway, et al.
Journal of Neurology|April 10, 2020
Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapyLe H Hua, Haleigh Harris, Devon Conway, et al.
Multiple Sclerosis and Related Disorders|March 10, 2019
Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60Le H Hua, Haleigh Harris, Devon Conway, et al.
Neurology. Clinical Practice|January 29, 2021
Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practiceCarrie M Hersh, Haleigh Harris, Devon Conway, et al.
Antiviral Research|December 15, 2010
Biodegradable nanogels for oral delivery of interferon for norovirus infectionYunjeong Kim, Mahendra Thapa, Duy H Hua, et al.
Pageof 29

Showing results (41-50 of 283) with videos related to

Sort By:
Pageof 29
Zhonghua Yi Xue Za Zhi|March 3, 2023
[Opportunities and prospects for sports medicine in China]S Y Chen, Y H Hua, T W Chen
Case Reports in Medicine|June 13, 2012
Concurrent stenoocclusive disease of intracranial and extracranial arteries in a patient with polycythemia veraLe H Hua, Robert L Dodd, Neil E Schwartz
Annals of Internal Medicine|September 15, 1993
A reassessment of the importance of "low-count" bacteriuria in young women with acute urinary symptomsC M Kunin, L V White, T H Hua
Zhonghua Kou Qiang Yi Xue Za Zhi = Zhonghua Kouqiang Yixue Zazhi = Chinese Journal of Stomatology|October 11, 2016
[Accuracy of three methods for the rapid diagnosis of oral candidiasis]X Lyu, C Zhao, Z M Yan, et al.
European Review for Medical and Pharmacological Sciences|August 1, 2019
MiRNA-191 functions as an oncogene in primary glioblastoma by directly targeting NDST1J Xue, M Yang, L-H Hua, et al.
Multiple Sclerosis and Related Disorders|April 17, 2019
Corrigendum to "Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60" [Multiple Sclerosis and Related Disorders 30 (2019) 252-256]Le H Hua, Haleigh Harris, Devon Conway, et al.
Journal of Neurology|April 10, 2020
Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapyLe H Hua, Haleigh Harris, Devon Conway, et al.
Multiple Sclerosis and Related Disorders|March 10, 2019
Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60Le H Hua, Haleigh Harris, Devon Conway, et al.
Neurology. Clinical Practice|January 29, 2021
Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practiceCarrie M Hersh, Haleigh Harris, Devon Conway, et al.
Antiviral Research|December 15, 2010
Biodegradable nanogels for oral delivery of interferon for norovirus infectionYunjeong Kim, Mahendra Thapa, Duy H Hua, et al.
Pageof 29